<DOC>
	<DOCNO>NCT01335165</DOCNO>
	<brief_summary>The purpose research study understand safety , pharmacokinetics pharmacodynamics single dose TT30 ( ALXN1102 ALXN1103 formulation ) give IV ( vein ) SC ( skin ) patient PNH .</brief_summary>
	<brief_title>Safety Pharmacokinetics TT30 Subjects With Paroxysmal Nocturnal Hemoglobinuria ( PNH )</brief_title>
	<detailed_description>This open-label , single-dose , dose-escalation study ass safety , tolerability , PK , PD , immunogenicity TT30 give IV infusion SC injection subject PNH evidence circulate PNH cell . Eligible subject PNH vaccinate meningococcal vaccine least two week prior dose ( previously vaccinate revaccination require ) . On study day 1 , subject receive single dose TT30 IV infusion 60 minute SC injection , follow additional study evaluation next 59 day .</detailed_description>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Individuals least 18 year age diagnosis PNH &amp; vaccination meningococcus . Abnormal renal liver function History meningococcal disease History GuillainBarre syndrome Known infection HIV Hepatitis B C History thrombotic event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>PNH</keyword>
</DOC>